Half-dose ocrelizumab in selected patients with relapsing-remitting multiple sclerosis

doi:10.1007/s13760-023-02303-0

. 2024 Feb;124(1):303-306.

doi: 10.1007/s13760-023-02303-0. Epub 2023 Jun 10.

Half-dose ocrelizumab in selected patients with relapsing-remitting multiple sclerosis

Hussein Algahtani^{1

2}, Bader Shirah³, Abdulhadi Alqahtani⁴, Nawal Abdelghaffar^{5

6}, Samiah Makki⁷

Affiliations

¹ Department of Medicine, Aseer Central Hospital, Abha, Saudi Arabia. halgahtani@hotmail.com.
² Neurology Section, Department of Medicine, King Abdulaziz Medical City, P.O. Box: 12723, Jeddah, 21483, Saudi Arabia. halgahtani@hotmail.com.
³ Department of Neuroscience, King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia.
⁴ College of Medicine, King Khalid University, Abha, Saudi Arabia.
⁵ Department of Medicine, Aseer Central Hospital, Abha, Saudi Arabia.
⁶ Neurology Department, Kasr Al Ainy Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt.
⁷ College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.

PMID: 37301802
PMCID: PMC10257484
DOI: 10.1007/s13760-023-02303-0

Half-dose ocrelizumab in selected patients with relapsing-remitting multiple sclerosis

Hussein Algahtani et al. Acta Neurol Belg. 2024 Feb.

. 2024 Feb;124(1):303-306.

doi: 10.1007/s13760-023-02303-0. Epub 2023 Jun 10.

Authors

Hussein Algahtani^{1

2}, Bader Shirah³, Abdulhadi Alqahtani⁴, Nawal Abdelghaffar^{5

6}, Samiah Makki⁷

Affiliations

¹ Department of Medicine, Aseer Central Hospital, Abha, Saudi Arabia. halgahtani@hotmail.com.
² Neurology Section, Department of Medicine, King Abdulaziz Medical City, P.O. Box: 12723, Jeddah, 21483, Saudi Arabia. halgahtani@hotmail.com.
³ Department of Neuroscience, King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia.
⁴ College of Medicine, King Khalid University, Abha, Saudi Arabia.
⁵ Department of Medicine, Aseer Central Hospital, Abha, Saudi Arabia.
⁶ Neurology Department, Kasr Al Ainy Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt.
⁷ College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.

PMID: 37301802
PMCID: PMC10257484
DOI: 10.1007/s13760-023-02303-0

No abstract available

Keywords: Half-dose; Multiple sclerosis; Ocrelizumab; Personalized.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

**Fig. 1**
MRI of the brain showing multiple high signal demyelinating plaques on T2-weighted images in the supra and infratentorial levels. On T1-weighted images, few holes were seen

**Fig. 2**
MRI of the spine showing a high signal demyelinating plaque in the spinal cord

See this image and copyright information in PMC

References

1. Dobson R, Giovannoni G. Multiple sclerosis—a review. Eur J Neurol. 2019;26(1):27–40. doi: 10.1111/ene.13819. - DOI - PubMed
1. Lamb YN. Ocrelizumab: a review in multiple sclerosis. Drugs. 2022;82(3):323–334. doi: 10.1007/s40265-022-01672-9. - DOI - PMC - PubMed
1. Tohyama S, Oh J, Timm M, et al. Should trigeminal neuralgia be considered a clinically isolated syndrome? Mult Scler. 2023;2:135245852211498. - PMC - PubMed
1. Syed YY. Ocrelizumab: a review in multiple sclerosis. CNS Drugs. 2018;32(9):883–890. doi: 10.1007/s40263-018-0568-7. - DOI - PubMed
1. Sabatino JJ, Zamvil SS, Hauser SL. B-cell therapies in multiple sclerosis. Cold Spring Harb Perspect Med. 2019;9(2):a032037. doi: 10.1101/cshperspect.a032037. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Dobson R, Giovannoni G. Multiple sclerosis—a review. Eur J Neurol. 2019;26(1):27–40. doi: 10.1111/ene.13819. - DOI - PubMed

[2] Dobson R, Giovannoni G. Multiple sclerosis—a review. Eur J Neurol. 2019;26(1):27–40. doi: 10.1111/ene.13819. - DOI - PubMed

[3] Lamb YN. Ocrelizumab: a review in multiple sclerosis. Drugs. 2022;82(3):323–334. doi: 10.1007/s40265-022-01672-9. - DOI - PMC - PubMed

[4] Lamb YN. Ocrelizumab: a review in multiple sclerosis. Drugs. 2022;82(3):323–334. doi: 10.1007/s40265-022-01672-9. - DOI - PMC - PubMed

[5] Tohyama S, Oh J, Timm M, et al. Should trigeminal neuralgia be considered a clinically isolated syndrome? Mult Scler. 2023;2:135245852211498. - PMC - PubMed

[6] Tohyama S, Oh J, Timm M, et al. Should trigeminal neuralgia be considered a clinically isolated syndrome? Mult Scler. 2023;2:135245852211498. - PMC - PubMed

[7] Syed YY. Ocrelizumab: a review in multiple sclerosis. CNS Drugs. 2018;32(9):883–890. doi: 10.1007/s40263-018-0568-7. - DOI - PubMed

[8] Syed YY. Ocrelizumab: a review in multiple sclerosis. CNS Drugs. 2018;32(9):883–890. doi: 10.1007/s40263-018-0568-7. - DOI - PubMed

[9] Sabatino JJ, Zamvil SS, Hauser SL. B-cell therapies in multiple sclerosis. Cold Spring Harb Perspect Med. 2019;9(2):a032037. doi: 10.1101/cshperspect.a032037. - DOI - PMC - PubMed

[10] Sabatino JJ, Zamvil SS, Hauser SL. B-cell therapies in multiple sclerosis. Cold Spring Harb Perspect Med. 2019;9(2):a032037. doi: 10.1101/cshperspect.a032037. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Half-dose ocrelizumab in selected patients with relapsing-remitting multiple sclerosis

Affiliations

Half-dose ocrelizumab in selected patients with relapsing-remitting multiple sclerosis

Authors

Affiliations

Conflict of interest statement

Figures

Similar articles

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical